Tibet Rhodiola Pharmaceutical Holding Co Net Assets

Latest as of June 2026: CN¥4.22 Billion CNY ≈ $618.09 Million USD

Tibet Rhodiola Pharmaceutical Holding Co net assets. Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has net assets worth CN¥4.22 Billion CNY (≈ $618.09 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.44 Billion ≈ $942.30 Million USD) and total liabilities (CN¥2.22 Billion ≈ $324.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 600211 net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥4.22 Billion
% of Total Assets 65.59%
Annual Growth Rate 20.68%
5-Year Change 57.49%
10-Year Change 532.89%
Growth Volatility 90.11

Net Assets of Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)

Net assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025. This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's net assets have evolved over time, based on quarterly financial data. See 600211 equity financing ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)

The table below shows the annual net assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025. For live market cap and overall valuation, see Tibet Rhodiola Pharmaceutical Holding Co market capitalisation.

Year Net Assets Change
2025-12-31 CN¥4.17 Billion
≈ $609.56 Million		 +5.40%
2024-12-31 CN¥3.95 Billion
≈ $578.32 Million		 +17.15%
2023-12-31 CN¥3.37 Billion
≈ $493.67 Million		 +11.31%
2022-12-31 CN¥3.03 Billion
≈ $443.50 Million		 +14.58%
2021-12-31 CN¥2.65 Billion
≈ $387.05 Million		 +2.19%
2020-12-31 CN¥2.59 Billion
≈ $378.76 Million		 +5.79%
2019-12-31 CN¥2.45 Billion
≈ $358.04 Million		 +8.40%
2018-12-31 CN¥2.26 Billion
≈ $330.29 Million		 +10.35%
2017-12-31 CN¥2.05 Billion
≈ $299.31 Million		 +210.76%
2016-12-31 CN¥658.19 Million
≈ $96.31 Million		 +35.46%
2015-12-31 CN¥485.90 Million
≈ $71.10 Million		 +17.32%
2014-12-31 CN¥414.18 Million
≈ $60.61 Million		 +3.75%
2013-12-31 CN¥399.20 Million
≈ $58.42 Million		 +3.57%
2012-12-31 CN¥385.44 Million
≈ $56.40 Million		 +8.59%
2011-12-31 CN¥354.94 Million
≈ $51.94 Million		 +9.48%
2010-12-31 CN¥324.19 Million
≈ $47.44 Million		 +8.06%
2009-12-31 CN¥300.00 Million
≈ $43.90 Million		 +7.47%
2008-12-31 CN¥279.15 Million
≈ $40.85 Million		 +1.78%
2007-12-31 CN¥274.28 Million
≈ $40.14 Million		 -30.80%
2006-12-31 CN¥396.34 Million
≈ $58.00 Million		 +0.79%
2005-12-31 CN¥393.25 Million
≈ $57.54 Million		 -9.70%
2004-12-31 CN¥435.51 Million
≈ $63.73 Million		 +2.59%
2003-12-31 CN¥424.53 Million
≈ $62.12 Million		 +1.36%
2002-12-31 CN¥418.85 Million
≈ $61.29 Million		 +3.04%
2001-12-31 CN¥406.50 Million
≈ $59.48 Million		 +1.03%
2000-12-31 CN¥402.35 Million
≈ $58.88 Million		 +3.24%
1999-12-31 CN¥389.71 Million
≈ $57.03 Million		 +285.93%
1998-12-31 CN¥100.98 Million
≈ $14.78 Million		 +18.33%
1997-12-31 CN¥85.34 Million
≈ $12.49 Million		 +376.84%
1996-12-31 CN¥17.90 Million
≈ $2.62 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Tibet Rhodiola Pharmaceutical Holding Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 250138699600.0% over the analyzed period, indicating profitable operations and earnings retention.

Tibet Rhodiola Pharmaceutical Holding Co Net Assets Breakdown (December 2025)

Tibet Rhodiola Pharmaceutical Holding Co net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Retained Earnings CN¥2.50 Billion 65.85%
Common Stock CN¥322.32 Million 8.49%
Other Comprehensive Income CN¥234.00 Million 6.16%
Other Components CN¥740.72 Million 19.50%
Total Equity CN¥3.80 Billion 100.00%

Tibet Rhodiola Pharmaceutical Holding Co Competitors by Market Cap

The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their market capitalization.

Company Market Cap
Newmark Group Inc
NASDAQ:NMRK
 $1.90 Billion
Per Aarsleff Holding A/S
CO:PAAL-B
 $1.91 Billion
KEPCO Engineering & Construction
KO:052690
 $1.91 Billion
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
 $1.91 Billion
Intapp Inc
NASDAQ:INTA
 $1.90 Billion
Sinomag Technology Co Ltd
SHE:300835
 $1.90 Billion
Alpha Metallurgical Resources Inc
NYSE:AMR
 $1.90 Billion
Stock Yards Bancorp Inc
NASDAQ:SYBT
 $1.90 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tibet Rhodiola Pharmaceutical Holding Co's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,917,817,000 to 3,798,429,273, a change of -119,387,727 (-3.0%).
  • Net income of 937,931,435 contributed positively to equity growth.
  • Dividend payments of 617,513,220 reduced retained earnings.
  • Other comprehensive income decreased equity by 13,853,766.
  • Other factors decreased equity by 425,952,176.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥937.93 Million +24.69%
Dividends Paid CN¥617.51 Million -16.26%
Other Comprehensive Income CN¥-13.85 Million -0.36%
Other Changes CN¥-425.95 Million -11.21%
Total Change CN¥- -3.05%

Book Value vs Market Value Analysis

This analysis compares Tibet Rhodiola Pharmaceutical Holding Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.43x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 620.39x to 3.43x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 CN¥0.07 CN¥40.37 x
1997-12-31 CN¥0.31 CN¥40.37 x
1998-12-31 CN¥0.35 CN¥40.37 x
1999-12-31 CN¥1.42 CN¥40.37 x
2000-12-31 CN¥1.46 CN¥40.37 x
2001-12-31 CN¥1.47 CN¥40.37 x
2002-12-31 CN¥1.51 CN¥40.37 x
2003-12-31 CN¥1.53 CN¥40.37 x
2004-12-31 CN¥1.55 CN¥40.37 x
2005-12-31 CN¥1.40 CN¥40.37 x
2006-12-31 CN¥1.85 CN¥40.37 x
2007-12-31 CN¥1.26 CN¥40.37 x
2008-12-31 CN¥1.38 CN¥40.37 x
2009-12-31 CN¥1.56 CN¥40.37 x
2010-12-31 CN¥1.19 CN¥40.37 x
2011-12-31 CN¥1.66 CN¥40.37 x
2012-12-31 CN¥1.82 CN¥40.37 x
2013-12-31 CN¥1.47 CN¥40.37 x
2014-12-31 CN¥1.52 CN¥40.37 x
2015-12-31 CN¥1.85 CN¥40.37 x
2016-12-31 CN¥2.49 CN¥40.37 x
2017-12-31 CN¥6.67 CN¥40.37 x
2018-12-31 CN¥6.89 CN¥40.37 x
2019-12-31 CN¥7.50 CN¥40.37 x
2020-12-31 CN¥8.01 CN¥40.37 x
2021-12-31 CN¥8.14 CN¥40.37 x
2022-12-31 CN¥9.33 CN¥40.37 x
2023-12-31 CN¥10.36 CN¥40.37 x
2024-12-31 CN¥12.15 CN¥40.37 x
2025-12-31 CN¥11.78 CN¥40.37 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tibet Rhodiola Pharmaceutical Holding Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 24.69%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 31.79%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 1.65x
  • Recent ROE (24.69%) is above the historical average (9.82%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 31.27% 25.84% 0.46x 2.64x CN¥3.81 Million
1997 23.29% 41.16% 0.40x 1.40x CN¥11.34 Million
1998 33.04% 40.91% 0.45x 1.79x CN¥22.27 Million
1999 8.49% 39.87% 0.19x 1.12x CN¥-5.90 Million
2000 7.73% 37.28% 0.16x 1.32x CN¥-9.12 Million
2001 4.53% 24.51% 0.12x 1.51x CN¥-22.12 Million
2002 2.46% 13.69% 0.10x 1.77x CN¥-31.24 Million
2003 1.37% 7.69% 0.10x 1.80x CN¥-36.24 Million
2004 1.43% 3.33% 0.24x 1.82x CN¥-36.54 Million
2005 -10.74% -5.93% 0.85x 2.13x CN¥-79.81 Million
2006 1.05% 0.47% 0.99x 2.23x CN¥-34.71 Million
2007 -46.53% -15.22% 0.99x 3.09x CN¥-152.19 Million
2008 2.35% 0.65% 1.19x 3.01x CN¥-21.08 Million
2009 6.85% 1.82% 1.49x 2.52x CN¥-9.27 Million
2010 7.37% 2.12% 1.51x 2.30x CN¥-8.39 Million
2011 6.03% 1.90% 1.37x 2.32x CN¥-13.48 Million
2012 8.21% 2.50% 1.45x 2.27x CN¥-6.63 Million
2013 6.99% 1.94% 1.23x 2.93x CN¥-11.71 Million
2014 5.19% 1.26% 1.59x 2.59x CN¥-19.46 Million
2015 18.72% 6.63% 1.96x 1.44x CN¥42.69 Million
2016 30.01% 24.89% 0.35x 3.47x CN¥132.23 Million
2017 11.24% 25.08% 0.39x 1.14x CN¥25.33 Million
2018 9.57% 20.98% 0.41x 1.12x CN¥-9.64 Million
2019 12.82% 24.87% 0.45x 1.14x CN¥68.62 Million
2020 16.23% 30.45% 0.47x 1.14x CN¥160.49 Million
2021 7.94% 9.77% 0.56x 1.45x CN¥-54.10 Million
2022 12.28% 14.48% 0.62x 1.36x CN¥68.67 Million
2023 23.95% 25.55% 0.68x 1.37x CN¥466.46 Million
2024 26.83% 37.46% 0.59x 1.21x CN¥659.51 Million
2025 24.69% 31.79% 0.47x 1.65x CN¥558.09 Million

Industry Comparison

This section compares Tibet Rhodiola Pharmaceutical Holding Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,554,577,785
  • Average return on equity (ROE) among peers: 7.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tibet Rhodiola Pharmaceutical Holding Co (600211) CN¥4.22 Billion 31.27% 0.52x $1.90 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.45 Billion 1.52% 1.57x $485.12 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $576.00 Million 3.15% 0.28x $363.11 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.12 Billion 13.25% 0.26x $4.79 Billion
Livzon Pharmaceutical Group Inc (000513) $623.47 Million 16.22% 0.40x $2.70 Billion
Wedge Industrial Co Ltd (000534) $654.70 Million 1.92% 0.87x $1.28 Billion
Yunnan Baiyao Group Co Ltd (000538) $184.00 Million 12.94% 0.09x $14.40 Billion
Hainan Haiyao Co Ltd (000566) $2.20 Billion -4.84% 2.35x $770.77 Million
Tus Pharmaceutical Group Co Ltd (000590) $728.20 Million 3.47% 0.58x $275.43 Million
Northeast Pharmaceutical Group Co Ltd (000597) $5.67 Billion 4.59% 1.27x $925.00 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $2.34 Billion 20.86% 0.40x $3.01 Billion

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.90 Billion
CN¥13.01 Billion CNY
Market Cap Rank
#6110 Global
#1155 in China
Share Price
CN¥40.37
Change (1 day)
-1.13%
52-Week Range
CN¥35.31 - CN¥47.72
All Time High
CN¥165.99
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more